VIRUS
Study Type
Performance
Human Hepatitis C (BVDV surrogate)
Clinical
>99% reduction within 30 seconds
Human Immunodeficiency (HIV-1/Mn)
In-vitro
>93.94% reduction within 30 seconds
>99.99% reduction within 2.5 minutes
Human Influenza A H1N1 (ATCC #VR-1520)
In-vitro
>99% reduction within 30 seconds
Avian Influenza H3N2 A/turkey/OH/31053/04)
In-vitro
>99% reduction within 30 seconds
Herpes Simplex Type I (HSV-1)
In-vitro
>68.74% reduction within 30 seconds
Acinetobacter baumannii (ATCC #19003)
Proteus mirabilis (ATCC #7002)
Acinetobacter baumannii (Clinical Isolate: BSLI #061901Ab3)
Proteus mirabilis (Clinical Isolate: BSLI #061901Pm2)
Bacteroides fragilis (ATCC #43858)
Pseudomonas aeruginosa (ATCC #15442)
Bacteroides fragilis (Clinical Isolate: BSLI #061901Bf6)
Pseudomonas aeruginosa (Clinical Isolate: BSLI #072605Pa)
Candida albicans (ATCC #10231)
Pseudomonas aeruginosa (ATCC #27853)
Candida albicans (Clinical Isolate: BSLI #042905Ca)
Pseudomonas aeruginosa (Clinical Isolate: BSLI #061901Pa2)
Clostridium difficile C-diff (ATCC #9689)
Serratia marcescens (ATCC #14756)
Enterobacter aerogenes (ATCC #29007)
Serratia marcescens (Clinical Isolate: BSLI #042905Sm)
Enterobacter aeruginosa (Clinical Isolate: BSLI #042905Ea)
Staphylococcus aureus aureus (ATCC #6538)
Enterococcus faecalis (ATCC #29212)
Staphylococcus aureus MRSA (ATCC #700698)
Enterococcus faecalis (Clinical Isolate: BSLI #061901Efs2)
Staphylococcus aureus VRSA (BSLI #062707NARSAVRSal)
Enterococcus faecium VRE, MDR (ATCC #51559)
Staphylococcus aureus (Clinical Isolate: BSLI #061901Sa1)
Enterococcus faecium (Clinical Isolate: BSLI #061901Efm1)
Staphylococcus aureus (ATCC #29213)
Escherichia coli (ATCC #11229)
Staphylococcus aureus (Clinical Isolate: BSLI #061901Sa2)
Escherichia coli (Clinical Isolate: BSLI #042905Ec1)
Staphylococcus epidermidis (ATCC #12228)
Escherichia coli (Clinical Isolate: BSLI #042905Ec2)
Staphylococcus epidermidis (Clinical Isolate: BSLI #072605Se)
Escherichia coli (ATCC #25922)
Staphylococcus haemolyticus (ATCC #29970)
Haemophilus influenzae (ATCC #8149)
Staphylococcus haemolyticus (Clinical Isolate: BSLI #042905Sha)
Haemophilus influenzae (Clinical Isolate: BSLI #072605Hi)
Staphylococcus hominis (ATCC #27844)
Klebsiella oxytoca MDR (ATCC #15764)
Staphylococcus hominis (Clinical Isolate: BSLI #042905Sho)
Klebsiella oxytoca (Clinical Isolate: BSLI #061901Ko1)
Staphylococcus saprophyticus (ATCC #35552)
Klebsiella pneumoniae subsp. ozaenae (ATCC #29019)
Staphylococcus saprophyticus (Clinical Isolate: BSLI #042905Ss)
Klebsiella pneumoniae (Clinical Isolate: BSLI #061901Kpn2)
Streptococcus pneumoniae (ATCC #33400)
Micrococcus luteus (ATCC #7468)
Streptococcus pneumoniae (Clinical Isolate: BSLI #072605Spn1)
Micrococcus luteus (Clinical Isolate: BSLI #061901M12)
Streptococcus pyogenes (ATCC #19615)
Neisseria gonorrhoeae (ATCC #19424)
Streptococcus pyogenes (Clinical Isolate: BSLI #061901Spy7)
Neisseria meningitidis (ATCC #13102)
BACTERIA:
MyClynsTM was tested using the standard OTC clinical (human) monograph test: Healthcare Personnel Handwash (HCPHW)
using Serratia marcescens. Immediate efficacy was shown after one application (>99% bacterial reduction).
In the bacteria listed below, a >99.99% reduction was also achieved in-vitro in 15 seconds:
Independent Laboratory Tests:
Spores:
Clostridium difficile (ATCC #700057) - >99.7% in-vitro reduction in 30 seconds
Bacillus atrophaeus (Anthrax surrogate) - >99.99% in-vitro reduction in 2 minutes
Mycobacteria:
Mycobacterium bovis - >99.9% in-vitro reduction in 60 seconds
Fungus:
Candida albicans (ATCC #10231 and Candida albicans (clinical isolate: BSLI #042905Ca) - >99.99% in-vitro reduction in 15 seconds
M
EDICAL
S
ALES
C
ONSULTANTS
A
USTRIA
G
MB
H
M
EDICAL
S
ALES
C
ONSULTANTS
G
ERMANY
G
MB
H
29
© 2005-2011
Medical Sales Consultants Austria GmbH. All rights reserved
A
UTHORIZED
D
ISTRIBUTOR
FOR
A
USTRIA
AND
G
ERMANY
First Response Spray
MyClynsTM